Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1107835rdf:typepubmed:Citationlld:pubmed
pubmed-article:1107835lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:1107835lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1107835lifeskim:mentionsumls-concept:C0030567lld:lifeskim
pubmed-article:1107835lifeskim:mentionsumls-concept:C0037663lld:lifeskim
pubmed-article:1107835lifeskim:mentionsumls-concept:C0003606lld:lifeskim
pubmed-article:1107835pubmed:issue11lld:pubmed
pubmed-article:1107835pubmed:dateCreated1976-4-2lld:pubmed
pubmed-article:1107835pubmed:abstractTextTo avoid the main drawbacks of prolonged treatment with levodopa (involuntary movements and the "on-off" phenomenon), we administered apomorphine by mouth to 14 patients with Parkinson's disease. This treatment caused azotemia, which we circumvented by switching to N-propylnoraporpine, whose nephrotoxic dose (80 mg six times per day) was larger than its therapeutic dose (10 to 15 mg six times per day). Slowly increasing doses induced significant improvement (P less than 0.005) in all 24 patients studied, transitory mental aberrations in seven, and release of growth hormone in three patients tested. In patients previously on prolonged levodopa administration, the dyskinesia and "on-off" phenomenon were almost identical with N-propylnoraporphine, but both drawbacks were reduced or abolished in six patients by coadministration of alpha-methyldopa hydrazine plus levodopa. This coadministration seemed to abolish tachyphylaxis. We conclude that N-propylnoraporphine is very useful in the treatment of Parkinson's disease.lld:pubmed
pubmed-article:1107835pubmed:languageenglld:pubmed
pubmed-article:1107835pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1107835pubmed:citationSubsetAIMlld:pubmed
pubmed-article:1107835pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1107835pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1107835pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1107835pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1107835pubmed:statusMEDLINElld:pubmed
pubmed-article:1107835pubmed:monthMarlld:pubmed
pubmed-article:1107835pubmed:issn0028-4793lld:pubmed
pubmed-article:1107835pubmed:authorpubmed-author:TolosaE SESlld:pubmed
pubmed-article:1107835pubmed:authorpubmed-author:CotziasG CGClld:pubmed
pubmed-article:1107835pubmed:authorpubmed-author:PapavasiliouP...lld:pubmed
pubmed-article:1107835pubmed:authorpubmed-author:MendezJ SJSlld:pubmed
pubmed-article:1107835pubmed:authorpubmed-author:Bell-MiduraMMlld:pubmed
pubmed-article:1107835pubmed:issnTypePrintlld:pubmed
pubmed-article:1107835pubmed:day11lld:pubmed
pubmed-article:1107835pubmed:volume294lld:pubmed
pubmed-article:1107835pubmed:ownerNLMlld:pubmed
pubmed-article:1107835pubmed:authorsCompleteYlld:pubmed
pubmed-article:1107835pubmed:pagination567-72lld:pubmed
pubmed-article:1107835pubmed:dateRevised2009-10-27lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:meshHeadingpubmed-meshheading:1107835-...lld:pubmed
pubmed-article:1107835pubmed:year1976lld:pubmed
pubmed-article:1107835pubmed:articleTitleTreatment of Parkinson's disease with aporphines. Possible role of growth hormone.lld:pubmed
pubmed-article:1107835pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1107835pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1107835pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:1107835pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1107835lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1107835lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1107835lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1107835lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1107835lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1107835lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1107835lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1107835lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1107835lld:pubmed